The trials were testing the efficacy of Keytruda, used in combination with standard multiple myeloma medications, to treat the blood cancer.
The FDA paused the trial after more patient deaths occurred among multiple myeloma patients taking the Keytruda immunotherapy regimen. Available data shows the risks of combining Keytruda with existing multiple myeloma drugs outweigh any possible benefits for this patient population, the FDA said.
At present, Keytruda is only approved to treat one form of blood cancer — classical Hodgkin’s lymphoma.
More articles on supply chain:
Britain looks to work with EU on drug regulation post-Brexit
St. Francis Medical Center receives Premier’s Supply Chain Excellence Award
Pharma looks to AI for streamlined drug development
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
